|
|
Through a combination of our internal efforts and aggressive
in-licensing, Archemix has consolidated the leading worldwide
intellectual property position for aptamer therapeutics. We own
or have licensed exclusive rights to over 200 issued patents and
approximately 250 pending patent applications pertaining
to the discovery and development
of aptamers and their role in treating disease.
ISIS Pharmaceuticals granted Archemix an exclusive license to chemistry patent rights to discover, develop and commercialize products containing aptamers. In addition, SomaLogic granted Archemix non-exclusive rights to their own and licensed intellectual property for the development and commercialization of aptamer therapeutics and specified nontherapeutic applications of aptamers including target validation.
We actively seek to protect our proprietary technology that we consider important to aptamer therapeutics
in the United States and other key pharmaceutical and pharmaceutical manufacturing markets. In this regard,
we have focused on patents, patent applications and other intellectual property covering:
- fundamental aspects of the identification, optimization, and structure of aptamers and their uses as
therapeutics;
- chemical modifications to aptamers that improve their suitability for therapeutic uses; and
-
aptamers directed to specific targets and as treatments for particular diseases.
Representative
examples of patents are listed below:
| Patent No |
Title |
Claim Summary |
| 5,475,096 |
Nucleic Acid Ligands |
Nucleic acid ligands to specified protein classes including
serine proteases, mammalian receptors, mammalian hormones,
and mammalian growth factors |
| 5,670,637 |
Nucleic Acid Ligands |
Nucleic acid ligands to proteins |
| 5,696,249 |
Nucleic Acid Ligands |
Nucleic acid ligands identified by SELEX |
| 6,331,398 |
Nucleic Acid Ligands |
Methods for identifying function modifying nucleic acid
ligands |
| Patent Pending |
Nucleic Acid Ligands |
Therapeutic compositions comprising nucleic acid ligands |
| 5,270,163 |
Nucleic Acid Ligands |
Methods for identifying nucleic acid ligands |
| 5,595,877 |
Methods of Producing Nucleic Acid Ligands |
Methods for identifying nucleic acid ligands having decreased
size, enhanced stability, or enhanced binding affinity |
| 5,817,785 |
Methods of Producing Nucleic Acid Ligands |
Nucleic acid ligands having decreased size, enhanced stability,
or enhanced binding affinity produced by the SELEX process |
| Patent Pending |
Methods of Producing Nucleic Acid Ligands |
Methods for identifying nucleic acid ligands having enhanced
target function altering activity and enhanced cell membrane
permeability |
| 6,344,318 |
Methods of Producing Nucleic Acid Ligands |
Methods for preparing modified nucleic acid ligands |
5,958,691
5,660,985 |
High Affinity Nucleic Acid Ligands Containing Modified Nucleotides |
Nucleic acid ligands with modified nucleotides |
| 5,567,588 |
Systematic Evolution of Ligands by Exponential Enrichment:
Solution SELEX |
Methods for identifying nucleic acid ligands by Solution
SELEX |
5,683,867
6,083,696
6,465,189 |
Systematic Evolution of Ligands by Exponential Enrichment:
Blended SELEX |
Methods for identifying nucleic acid ligands comprising
a functional unit; nucleic acid ligands identified by said
methods |
5,637,459
5,773,598 |
Systematic Evolution of Ligands by Exponential Enrichment:
Chimeric SELEX |
Methods for identifying chimeric nucleic acid ligands having
high binding affinity for first and second target molecules |
5,705,337
5,962,219
5,763,595
6,300,074
5,998,142 |
Systematic Evolution of Ligands By Exponential Enrichment:
Chemi-SELEX |
Methods for identifying nucleic acid ligands that bind covalently
with a target molecule |
| 6,011,020 |
Nucleic Acid Ligand Complexes |
Therapeutic complexes comprised of a nucleic acid ligand
and polyethylene glycol |
6,147,204
6,465,188 |
Nucleic Acid Ligand Complexes |
Therapeutic complexes comprised of a nucleic acid ligand
and a lipophilic compound or a non-immunogenic, high molecular
weight compound |
5,789,157
5,864,026
5,712,375
5,763,566
6,013,443
6,376,474
6,613,526 |
Systematic Evolution of Ligands by Exponential Enrichment:
Tissue SELEX |
Methods for identifying nucleic acid ligands to a protein
component of a biological tissue |
| 6,114,120 |
Systematic Evolution of Ligands by Exponential Enrichment:
Tissue SELEX |
Nucleic acid ligands to cell macromolecules |
| 6,261,774 |
Truncation SELEX Method |
Methods for identifying nucleic acid ligands of a target
molecule |
| 6,387,620 |
Transcription-Free SELEX |
Methods for identifying nucleic acid ligands of a target
compound without transcription |
| EP 0 553 838 |
Nucleic Acid Ligands |
Methods for identifying nucleic acid ligands |
| EP 0 786 469 |
Methods of Use of Nucleic Acid ligands |
Uses of nucleic acid ligands in the manufacture of therapeutic
agent including agents wherein the aptamer modifies, e.g.,
inhibits or activates, a function of the target molecule,
affects the catalytic activity of enzymes, affects the functionality
of protein receptors, affects the formation of protein multimers,
inhibits binding to receptors, modifies the specificity of
binding to receptors, modifies hormone action, modifies the
transport properties of proteins, or acts as a drug delivery
vehicle |
| EP 0 668 931 |
Nucleic Acid Ligands and Methods for Producing the Same |
Methods for identifying nucleic acid ligands with improved
characteristics including decreased size, improved stability,
improved target binding, resistance to clearance, the capability
to cross tissue or cell membrane barriers, or the ability
to modify the biological activity of the target |
|
|
